References — "Statins and Cancer," Townsend Letter FEB/MAR 2008

1. Guyton A, Hall J. *Textbook of Medical Physiology*. 9th ed. Philadelphia, PA: W.B. Saunders; 1996:873.
2. Alsheikh-Ali A, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated enzymes, rhabdomyolysis, and cancer. *J Am Coll Cardiol*. 2007;50:409-418.
3. Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. *JAMA*. 1994;272:1335-1340.
4. Colpo A. LDL Cholesterol: 'Bad' cholesterol or bad science. *J Am Phys Surg*. 2005;10:83-89.
5. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. *JAMA*. 1996; 275:55-60.
6. Goldstein MR. Lipid-altering drugs: Decreasing cardiovascular disease at the expense of increasing colon cancer? *Cancer Res*. 2004;64:6831-6832.
7. Felton CV, Crook D, Davies MJ, Oliver MF. Dietary polyunsaturated fatty acids and composition of human aortic plaques. *Lancet*. 1994;344:1195-1196.
8. Waddington E, Sienuarine K, Puddey I, Croft K. Identification and quantification of unique fatty acid and oxidative products in human atherosclerotic plaque using high-performance lipid chromatography. *Anal Biochem*. 2001;292:234-244.

9. Kuhn H, Belkner J, Wiesner R, Schewe T, Lankin VZ, Tikhaze AK. Structure elucidation of oxygenated lipids in human atherosclerotic lesions. *Eicosanoids*. 1992;5:17-22.
10. Guyton A, Hall J. *Textbook of Medical Physiology*. 9th ed. Philadelphia, PA: W.B. Saunders; 1996:873,958,1010.
11. Alberts B. Bray D, Lewis J, Raff M, Roberts K, Watson JD. *Molecular Biology of the Cell*. 3rd ed. New York: Garland; 1994:481.
12. Voet D, Voet JG. *Biochemistry Vol. 1: Biomolecules, Mechanisms of Enzyme Action, and Metabolism*. 3rd ed. Wiley, NY; 2003:439.
13. Bowen PE, Borthakur G. Postprandial lipid oxidation and cardiovascular disease risk. *Curr Atheroscler Rep*. 2004;6:477-484.
14. Sinclair HM. Essential fatty acids in perspective. Hum Nutrit. 1984;38C:245-260.
15. Kelsey FE, Longenecker HE. *J. Biol. Chem*. 1941;139:727.
16. Salem N, Lin Y, Brenna JT, Pawlosky RJ. Alpha-linolenic acid conversion revisited. PUFA Newsletter, December 2003. Retrieved October 12, 2007. Available at: http://www.fatsoflife.com/pufa/article.asp?edition=arch&id=162&nid=1.
17. Pawlosky RJ, Hibbeln JR, Novotny JA, Salem N Jr. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. *J Lipid Res.* 2001;42:1257-1265.

18. Goyens PLL, Spilker ME, Zock PL, Katan MB, Mensink RP. Conversion of alpha-linolenic acid in humans is influenced by the absolute amounts of alpha-linolenic acid and linoleic acid in the diet and not by their ratio. *Am J Clin Nutr*. 2006;84:44-53.

19. Murray RK, Granner DK, Mayes PA, Rodwell VW. *Harper's Illustrated Biochemistry*. 26th ed. New York: McGraw Hill; 2003:191-192.

20. Meisenberg G, Simmons WH. *Principles of Biomedical Chemistry*. 1st edition. St. Louis, MO: Mosby; 1998:226.

21. Vidgren HM, Louheranta AM, Agreb JJ, Scwab US, Uusitupa MI. Divergent incorporation of dietary trans fatty acids in different serum lipid fractions. *Lipids*. 1998;33:955-962.

22. Ibrahim A, Natrajan S, Ghafoorunissa R. Dietary trans-fatty acids alter adipocyte plasma membrane fatty acid composition and insulin sensitivity in rats. *Metabolism*. 2005;54:240-246.

23. Berlin E, Bhathena SJ, McClure D, Peters RC. Dietary menhaden and corn oils and the red blood cell membrane lipid composition and fluidity in hyper- and normocholesterolemic miniature swine. *J Nutr*. 1998;128:1421-1428.

24. Sundram K, Karupaiah T, Hayes KC. Stearic acid–rich interesterified fat and trans-rich fat raise the LDL/HDL ratio and plasma glucose relative to palm olein in humans. *Nutr Metab*. (Lond) 2007;4:3.

25. Prades J, Funari S, Escribá PV, Barceló F. Effects of unsaturated fatty acids and triacylglyerols on phosphatidylethanolamine membrane structure. *J Lipid Res*. 2003;44:1720-1727.
26. Hu FB, Stampfer MJ, Manson JE, et al. Dietary fat intake and the risk of coronary heart disease in women. *N Engl J Med*. 1997;337:1491-1499.
27. Warburg, O. The metabolism of carcinoma cells. *J Cancer Res*. 1925;9:148-163.
28. Warburg, O. On the origin of cancer cells. *Science*. 1956;123:309-314.
29. Goldblatt H, Cameron G. Induced malignancy in cells from rat myocardium subjected to intermittent anaerobiosis during long propagation in vitro. *J Exp Med*. 1953;97:525-552.
30. Malmgren, RA, Flanigan CC. Localization of the vegetative form of *Clostridium tetani* in mouse tumors following intravenous spore administration. *Cancer Res*. 1955;15:473-478.
31. Warburg, O. The Metabolism of Tumours: Investigations from the Kaiser Wilhelm Institute for Biology, translated by Frank Dickens. Constable & Co Ltd: 1930 (out of print).
32. Campbell IM, Crozier DN, Caton RB. Abnormal fatty acid composition and impaired oxygen supply in cystic fibrosis patients. *Pediatrics*. 57, 480-486, 1976.
33. Guyton AC, Hall JE. *Textbook of Medical Physiology*. 10th ed. Philadelphia: W.B. Saunders Co.; 2000:874.

34. Weinberg RA. *One Renegade Cell: How Cancer Begins*. *New York:* Basic Books; 1998: 146.

35. Wood S Jr. Pathogenesis of metastasis formation observed in vivo in the rabbit ear chamber. *AMA Arch Pathol*. 1958;66:550-568.

36. Bunting S, Moncada S, Vane JR. The prostacyclin—thromboxane A2 Balance: Pathophysiological and therapeutic implications. *BMJ*. 1983;39:271-276.

37. Sinclair HM. Deficiency of essential fatty acids and atherosclerosis, etcetera. *Lancet*. 1956;270:381-383.

38. Chapkin RS, Ziboh VA, Marcelo CL, Voorhees JJ. Metabolism of essential fatty acids by human epidermal enzyme preparations: evidence of chain elongation. *J Lipid Res*. 1986;27:945-954.

39. Andersson A, Sjödin A, Hedman A, Olsson R, Vessby B. Fatty acid profile of skeletal muscle phospholipids in trained and untrained young men. *Am J Physiol Endocrinol Metab* 2000;279:E744–751.

40. Miettinen TA, Naukkarinen V, Huttunen JK, Mattila S, Kumlin T. Fatty acid composition of serum lipids predicts myocardial infarction. *BMJ*. 1982;285:993-996.

41. Peskin BS. Scientific calculation of the optimum PEO ratio. Parent essential oils: omega-6/3 defined. Cambridge International Institute for Medical Science; 2006. Retrieved October 10, 2007. Available from http://www.CambridgeMedScience.org.